LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Elenco Azioni・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

17.37 1.28

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

17.09

Massimo

17.49

Metriche Chiave
By Trading Economics
Entrata	-607K -51M
Vendite	-28M 100M
EPS	-0.46
Margine di Profitto	-51.215
Dipendenti	1,784
EBITDA	4.1M -44M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+88.7% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-541M 1.8B
Apertura precedente	16.09
Chiusura precedente	17.37

Notizie sul Sentiment di mercato

By Acuity

34%

66%

87 / 344 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 giu 2026, 21:51 UTC

I principali Market Mover

Merlin Shares Rally After Defense Department's Design Review Wraps

4 giu 2026, 23:46 UTC

Discorsi di Mercato

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 giu 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 giu 2026, 23:42 UTC

Acquisizioni, Fusioni, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 giu 2026, 23:41 UTC

Acquisizioni, Fusioni, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 giu 2026, 23:34 UTC

Discorsi di Mercato

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

4 giu 2026, 23:08 UTC

Discorsi di Mercato

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 giu 2026, 22:41 UTC

Discorsi di Mercato

Australia Shares Set to Rise at the Open -- Market Talk

4 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

4 giu 2026, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 giu 2026, 20:16 UTC

Discorsi di Mercato

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 giu 2026, 19:46 UTC

Discorsi di Mercato

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 giu 2026, 19:38 UTC

Discorsi di Mercato

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 giu 2026, 19:30 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 giu 2026, 18:47 UTC

Acquisizioni, Fusioni, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 giu 2026, 18:38 UTC

Utili

Money Quote: Tech Weakness in Context -- WSJ

4 giu 2026, 18:24 UTC

Utili

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 giu 2026, 17:09 UTC

Discorsi di Mercato

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 giu 2026, 16:58 UTC

Utili

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 giu 2026, 16:46 UTC

Discorsi di Mercato

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 giu 2026, 16:38 UTC

Utili

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

4 giu 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

4 giu 2026, 16:13 UTC

Discorsi di Mercato

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 giu 2026, 16:11 UTC

Discorsi di Mercato

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 giu 2026, 15:56 UTC

Discorsi di Mercato

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

88.7% in crescita

Previsioni per 12 mesi

Media 32.4 USD 88.7%

Alto 44 USD

Basso 21.6 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

87 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.